Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014). Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). American Diabetes Association.
Citação norma ChicagoNauck, Michael, Ruth S. Weinstock, Guillermo E. Umpierrez, Bruno Guerci, Zachary Skrivanek, and Zvonko Milicevic. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). American Diabetes Association, 2014.
ציטוט MLANauck, Michael, et al. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). American Diabetes Association, 2014.